Literature DB >> 32475471

Links between cancer metabolism and cisplatin resistance.

Veronica Cocetta1, Eugenio Ragazzi1, Monica Montopoli2.   

Abstract

Cisplatin is one of the most potent and widely used chemotherapeutic agent in the treatment of several solid tumors, despite the high toxicity and the frequent relapse of patients due to the onset of drug resistance. Resistance to chemotherapeutic agents, either intrinsic or acquired, is currently one of the major problems in oncology. Thus, understanding the biology of chemoresistance is fundamental in order to overcome this challenge and to improve the survival rate of patients. Studies over the last 30 decades have underlined how resistance is a multifactorial phenomenon not yet completely understood. Recently, tumor metabolism has gained a lot of interest in the context of chemoresistance; accumulating evidence suggests that the rearrangements of the principal metabolic pathways within cells, contributes to the sensitivity of tumor to the drug treatment. In this review, the principal metabolic alterations associated with cisplatin resistance are highlighted. Improving the knowledge of the influence of metabolism on cisplatin response is fundamental to identify new possible metabolic targets useful for combinatory treatments, in order to overcome cisplatin resistance.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer metabolism; Cisplatin; Drug resistance; Glutamine; Glycolysis; Lipid metabolism; Metabolic reprogramming; Metabolic targets; Mitochondria; PPP

Mesh:

Substances:

Year:  2020        PMID: 32475471     DOI: 10.1016/bs.ircmb.2020.01.005

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  13 in total

1.  [RUNX3 regulates trastuzumab resistance of gastric cancer cells: a metabolomic analysis based on UPLC-Q Exactive Focus Orbitrap mass spectrometry].

Authors:  W Liu; J Tang; J Chang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

2.  G protein subunit gamma 5 promotes the proliferation, metastasis and glycolysis of breast cancer cells through the Wnt/β-catenin pathway.

Authors:  Zuguo Yuan; Ruiping Ren; Zhengyang Xu
Journal:  Anticancer Drugs       Date:  2022-09-29       Impact factor: 2.389

Review 3.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

Review 4.  Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.

Authors:  Isabella Giacomini; Federico Gianfanti; Maria Andrea Desbats; Genny Orso; Massimiliano Berretta; Tommaso Prayer-Galetti; Eugenio Ragazzi; Veronica Cocetta
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 5.  Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives.

Authors:  Veronica Cocetta; Vincenzo Quagliariello; Francesco Fiorica; Massimiliano Berretta; Monica Montopoli
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

6.  Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer.

Authors:  Yanlong Zhang; Xuezhi Liang; Liyun Zhang; Dongwen Wang
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

7.  Upregulation of Yin-Yang-1 Associates with Proliferation and Glutamine Metabolism in Esophageal Carcinoma.

Authors:  Can Luo; Xin Chen; Yuting Bai; Lei Xu; Shuqi Wang; Lihua Yao; Xiaolan Guo; Dongsheng Wang; Xiaowu Zhong
Journal:  Int J Genomics       Date:  2022-03-20       Impact factor: 2.326

8.  Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.

Authors:  Ricardo Noriega-Rivera; Mariela Rivera-Serrano; Robert J Rabelo-Fernandez; Josué Pérez-Santiago; Fatima Valiyeva; Pablo E Vivas-Mejía
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

9.  Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis.

Authors:  Jingjing Ge; Baohong Wang; Shuai Zhao; Jiaju Xu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

Review 10.  Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer.

Authors:  Zhengwei Wu; Yi Fei Lee; Xun Hui Yeo; Ser Yue Loo; Wai Leong Tam
Journal:  Cancers (Basel)       Date:  2021-03-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.